Publications by authors named "Cora S Hedrich"
Cancers (Basel)
October 2022
Article Synopsis
- Medulloblastoma (MB) recurrence is hard to cure, even with high-dose chemotherapy, leading to a new approach focused on targeting tumor blood vessel growth.
- A study reviewed 29 patients treated with a unique combination of oral and intravenous medications following the MEMMAT strategy before the formal protocol began.
- The results showed promising survival rates, with a median overall survival of 29.5 months, and some patients surviving long-term, indicating that this antiangiogenic therapy could enhance outcomes for recurrent MB.
